BioSpace News Archive

Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences.

NLS Pharmaceutics Ltd. announced the closing of its previously announced registered direct offering with health-care focused institutional investors alongside participation from the Company’s Chairman of the Board of Directors, Ronald Hafner, for the purchase and sale of 4,200,000 of the Company’s common shares at a purchase price of $1.04 per common share.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody lecanemab in people living with early Alzheimer’s disease (AD) using simulation modeling was published in a peer-reviewed journal Neurology and Therapy.

Infinity Fuel Cell and Hydrogen, Inc., a global leader in hydrogen fuel cells and electrolyzers for aerospace applications, today announced signing a contract add-on with NASA’s Game Changing Development program and NASA’s Glenn Research Center in Cleveland, Ohio.

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), today announced that it has filed a clinical trial application with the Human Research Ethics Committee (HREC) in Australia in order to initiate the Phase I ATRIUM trial of ATG-018 in patients with advanced solid tumors and hematologic malignancies.

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Aclarion, Inc. announced the closing of its previously announced initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock.

RVAC Medicines Pte. Ltd., an emerging messenger RNA platform company incubated in Singapore by CBC Group, announced the completion of its series B financing, bringing the company’s total funds raised since its inception in June 2021 to US$140 million.

Zymo Research and Star Array announced Zymo Research’s strategic investment to acquire an interest in Star Array, a privately owned, biomedical technology company based in Singapore.